Preparation and cytotoxicity of cisplatin-containing liposomes

被引:56
作者
Carvalho Junior, A. D., Jr.
Vieira, F. P.
De Melo, V. J.
Lopes, M. T. P.
Silveira, J. N.
Ramaldes, G. A.
Garnier-Suillerot, A.
Pereira-Maia, E. C.
De Oliveira, M. C.
机构
[1] Univ Fed Minas Gerais, Fac Farm, Dept Prod Farmaceut, BR-31270901 Belo Horizonte, MG, Brazil
[2] Univ Fed Minas Gerais, Fac Farm, Dept Anal Clin & Toxicol, BR-31270901 Belo Horizonte, MG, Brazil
[3] Univ Fed Minas Gerais, Inst Ciencias Exatas, Dept Quim, BR-31270901 Belo Horizonte, MG, Brazil
[4] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Farmacol, BR-31270901 Belo Horizonte, MG, Brazil
[5] Univ Paris 13, Lab BioMoCeTi, UMR 7033, Paris, France
关键词
cisplatin; liposomes; encapsulation; cytotoxicity;
D O I
10.1590/S0100-879X2006005000125
中图分类号
Q [生物科学];
学科分类号
07 [理学]; 0710 [生物学]; 09 [农学];
摘要
We encapsulated cisplatin into stealth pH-sensitive liposomes and studied their stability, cytotoxicity and accumulation in a human small-cell lung carcinoma cell line (GLC4) and its resistant subline (GLC4/CDDP). Since reduced cellular drug accumulation has been shown to be the main mechanism responsible for resistance in the GLC4/CDDP subline, we evaluated the ability of this new delivery system to improve cellular uptake. The liposomes were composed of dioleoylphosphatidylethanolamine (DOPE), cholesteryl hemisuccinate (CHEMS), and distearoylphosphatidylethanolamine-polyethyleneglycol 2000 (DSPE-PEG(2000)) and were characterized by determining the encapsulation percentage as a function of lipid concentration. Among the different formulations, DOPE/CHEMS/DSPE-PEG liposomes (lipid concentration equal to 40 mM) encapsulated cisplatin more efficiently than other concentrations of liposomes (about 20.0%, mean diameter of 174 nm). These liposomes presented good stability in mouse plasma which was obtained using a 0.24-M EDTA solution (70% cisplatin was retained inside the liposomes after 30 min of incubation). Concerning cytotoxic effects, they are more effective (1.34-fold) than free cisplatin for growth inhibition of the human lung cancer cell line A549. The study of cytotoxicity to GLC4 and GLC4/ CDDP cell lines showed similar IC50 values (approximately 1.4 mu M), i.e., cisplatin-resistant cells were sensitive to this cisplatin formulation. Platinum accumulation in both sensitive and resistant cell lines followed the same pattern, i.e., approximately the same intracellular platinum concentration (4.0 x 10(-17) mol/cell) yielded the same cytotoxic effect. These results indicate that long-circulating pH-sensitive liposomes, also termed as stealth pH-sensitive liposomes, may present a promising delivery system for cisplatin-based cancer treatment. This liposome system proved to be able to circumvent the cisplatin resistance, whereas it was not observed when using non-long-circulating liposomes composed of phosphatidylcholine, phosphatidylserine, and cholesterol.
引用
收藏
页码:1149 / 1157
页数:9
相关论文
共 34 条
[1]
ANDREWS PA, 1991, CANCER RES, V51, P3677
[2]
Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and -resistant cells [J].
Beretta, GL ;
Gatti, L ;
Tinelli, S ;
Corna, E ;
Colangelo, D ;
Zunino, F ;
Perego, P .
BIOCHEMICAL PHARMACOLOGY, 2004, 68 (02) :283-291
[3]
Synthesis, characterization, cytotoxic activity, and cellular accumulation of dinuclear platinum complexes derived from N,N′-di-(2-aminoethyl)-1,3-diantino-2-propanol, aryl substituted N-benzyl-1,4-butanediamines, and N-benzyl-1,6-hexanediamines [J].
Cesar, ET ;
de Almeida, MV ;
Fontes, APS ;
Pereira, EC ;
Garnier-Suillerot, MA ;
Couri, MRC ;
Felício, EDA .
JOURNAL OF INORGANIC BIOCHEMISTRY, 2003, 95 (04) :297-305
[4]
CHU G, 1994, J BIOL CHEM, V269, P787
[5]
Collins D., 1995, LIPOSOMES TOOLS BASI, P201
[6]
Clinical Pharmacology of Intraperitoneal Cisplatin-Based Chemotherapy [J].
Conti, M. ;
de Giorgi, U. ;
Tazzari, V. ;
Bezzi, F. ;
Baccini, C. .
JOURNAL OF CHEMOTHERAPY, 2004, 16 :23-25
[7]
Improvement of in vivo stability of phosphodiester oligonucleotide using anionic liposomes in mice [J].
De Oliveira, MC ;
Boutet, V ;
Fattal, E ;
Boquet, D ;
Grognet, JM ;
Couvreur, P ;
Deverre, JR .
LIFE SCIENCES, 2000, 67 (13) :1625-1637
[8]
Preferential energy- and potential-dependent accumulation of cisplatin-gutathione complexes in human cancer cell lines (GLC4 and k562): A likely role of mitochondria [J].
Dzamitika, Simplice ;
Salerno, Milena ;
Pereira-Maia, Elene ;
Le Moyec, Laurence ;
Garnier-Suillerot, Arlette .
JOURNAL OF BIOENERGETICS AND BIOMEMBRANES, 2006, 38 (01) :11-21
[9]
High-dose cisplatin with amifostine: Ototoxicity and pharmacokinetics [J].
Ekborn, A ;
Hansson, J ;
Ehrsson, H ;
Eksborg, S ;
Wallin, I ;
Wagenius, G ;
Laurell, G .
LARYNGOSCOPE, 2004, 114 (09) :1660-1667
[10]
CELLULAR ACCUMULATION OF THE ANTICANCER AGENT CISPLATIN - A REVIEW [J].
GATELY, DP ;
HOWELL, SB .
BRITISH JOURNAL OF CANCER, 1993, 67 (06) :1171-1176